L-Carnitine L-Tartrate Cas:36687-82-8

We are L-Carnitine L-Tartrate CAS:36687-82-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Name: L-Carnitine L-Tartrate
Product packaging: 25kg cardboard barrel
Molecular formula:C18H36N2O12
Molecular weight: 472.49
CAS: 36687-82-8

Appearance and properties: L-carnitine tartrate is a stable form of L-carnitine. It is not easy to absorb moisture and remains stable under wet conditions. It is a white crystalline powder with a unique acidic smell. It is soluble in water, but not in organic solvents.

Physical and chemical properties:

Check Item	Specification
Identification	In accordance with the IR absorption spectrum of the standard
Appearance	White Crystals or White Crystalline Powder
Particle size (mesh)	Through 20mesh
Specific rotation	-9.5~ -11.0
pH	3.0~4.5
Loss on drying	≤0.50%
Residue on ignition	≤0.50%
Residual solvents (Ethanol)	≤0.5%
Solubility	Clarification
Cyanide	Non detectable
Heavy metal	≤10ppm
Arsenic (As)	≤1ppm
Lead （Pb）	≤3ppm
Cadmium (Cd)	≤1ppm
Mercury （Hg）	≤0.1ppm
TPC	≤1000Cfu/g
Yeast & Mold	≤ 100Cfu/g
E.Coli	Negative
Salmonella	Negative
L-Carnitine content	68.2±1.0%
L-Tartaric acid content	31.8±1.0%

Main uses: L-carnitine tartrate is an ideal form of L-carnitine. It is suitable for solid preparations, especially tablets and capsules. It is used as feed nutrition enhancer, medical and health products and food additives.

L-Carnitine L-Tartrate can be used in Food, Beverage, Pharmaceutical, Health & Personal care products, Agriculture/Animal Feed/Poultry. L-Carnitine L-Tartrate is a functional food additive used for protein supplementation. L-Carnitine L-Tartrate can be used in health products, sports beverages, and infant food.

Market News:Immunocompromised people account for roughly 2.7% of U.S. adults including patients who’ve received an organ transplant, living with HIV or have received active or recent treatment for cancer, Oliver said. 4,4′-(hydroxyphosphoryl)dibenzoic acid manufacturer.In SLE, along with the pivotal TULIP phase III programme, anifrolumab continues to be evaluated in a long-term extension phase III trial.12 A phase II trial of anifrolumab in SLE using subcutaneous delivery has been completed. Benzamide, N-[1-(aminocarbonyl)-1,2-dimethylpropyl]-2,4-dimethyl- supplier.The manufacturing chief pointed to some of the cutting-edge technology Takeda will roll out at the upgraded facility, such as automation and robotics, plus virtual reality equipment and training. mer-[Mn(I)(1,10-phenanthroline)(CO)3(2-phenyl-imidazole)] producer.